{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:46Z","timestamp":1785132106119,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"\n Background<\/jats:title>\n Diabetic kidney disease (DKD) is a major complication of type 2 diabetes (T2D) and is closely linked to metabolic dysregulation. The uric acid-to-high-density lipoprotein cholesterol ratio (UHR) integrates urate-related purine metabolism and high-density lipoprotein cholesterol (HDL-C)-related lipid metabolism, two metabolic signals potentially related to kidney injury. This study examined the cross-sectional association between UHR and prevalent DKD in patients with T2D.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This study included a primary clinical cohort of 912 patients with T2D and an external validation cohort from the National Health and Nutrition Examination Survey (NHANES;\n n<\/jats:italic>\n = 2,738). Multivariable logistic regression was used to assess the association between UHR and prevalent DKD. Restricted cubic spline (RCS) analyses evaluated exposure-response patterns. Subgroup, interaction, and joint analyses were performed to examine the association across clinical strata.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the primary cohort, DKD prevalence increased from 20.52% in the lowest UHR quartile to 55.26% in the highest quartile (\n P<\/jats:italic>\n &lt; 0.001). After full adjustment, each 1-SD increase in UHR was associated with more than 2-fold higher odds of DKD (OR, 2.22; 95% CI, 1.80\u20132.77;\n P<\/jats:italic>\n &lt; 0.001). Compared with Q1, the adjusted ORs for Q2, Q3, and Q4 were 1.29, 2.32, and 6.73, respectively. The trend across quartiles was significant (\n P<\/jats:italic>\n for trend &lt; 0.001). RCS analyses showed positive overall associations between UHR and DKD. The positive association was generally observed across predefined subgroups, with nominal evidence of interaction by body mass index (BMI) and insulin use. In NHANES, 1,067 of 2,738 participants had DKD. External validation showed directionally consistent results. Higher odds of DKD were observed per 1-SD increase in UHR (OR, 1.44; 95% CI, 1.23\u20131.68;\n P<\/jats:italic>\n &lt; 0.001) and in Q4 vs. Q1 (OR, 2.61; 95% CI, 1.79\u20133.79;\n P<\/jats:italic>\n &lt; 0.001). Survey-weighted RCS showed a positive association without significant non-linearity.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Higher UHR was associated with greater odds of prevalent DKD in the hospital-based T2D cohort, with directionally consistent findings in the NHANES validation cohort.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fnut.2026.1887095","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:55Z","timestamp":1785130855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-sectional association of the uric acid-to-HDL cholesterol ratio with diabetic kidney disease in patients with type 2 diabetes"],"prefix":"10.3389","volume":"13","author":[{"given":"Yongjun","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Practice, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American","year":"2024","journal-title":"Diab Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1513008","DOI":"10.3389\/fendo.2025.1513008","article-title":"Global burden of chronic kidney disease due to diabetes mellitus, 1990-2021, and projections to (2050)","volume":"16","author":"Ma","year":"2025","journal-title":"Front Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/jcm12082759","article-title":"Recent advances and remaining challenges in the management of diabetic kidney disease","volume":"12","author":"Gervasini","year":"2023","journal-title":"J Clin Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving global outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1697943","DOI":"10.3389\/fnut.2025.1697943","article-title":"Remnant cholesterol for diabetic kidney disease risk stratification in type 2 diabetes: a machine learning-based prevention tool","volume":"12","author":"Dai","year":"2025","journal-title":"Front Nutr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/biomedicines12051098","article-title":"Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions","volume":"12","author":"Jha","year":"2024","journal-title":"Biomedicines."},{"key":"B7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41419-024-06833-0","article-title":"Mitochondrial metabolic reprogramming in diabetic kidney disease","volume":"15","author":"Fan","year":"2024","journal-title":"Cell Death Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"108929","DOI":"10.1016\/j.jdiacomp.2024.108929","article-title":"Uric acid in diabetic microvascular complications: mechanisms and therapy","volume":"39","author":"Li","year":"2025","journal-title":"J Diabetes Complications."},{"key":"B9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13098-025-01656-1","article-title":"High levels of serum uric acid are associated with microvascular complications in patients with long-term diabetes","volume":"17","author":"Wang","year":"2025","journal-title":"Diabetol Metab Syndr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/jpm14090996","article-title":"Dysfunctional high-density lipoprotein cholesterol and coronary artery disease: a narrative review","volume":"14","author":"Madaudo","year":"2024","journal-title":"J Pers Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/antiox14040434","article-title":"HDL-Cholesterol and triglycerides dynamics: essential players in metabolic syndrome","volume":"14","author":"Alcover","year":"2025","journal-title":"Antioxidants."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/ijms26041683","article-title":"High-density lipoprotein in patients with diabetic kidney disease: friend or foe?","volume":"26","author":"Liu","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1186\/s40001-025-03465-8","article-title":"Association between the serum uric acid-to-high-density lipoprotein cholesterol ratio and microalbuminuria in individuals with type 2 diabetes mellitus","volume":"30","author":"Qian","year":"2025","journal-title":"Eur J Med Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e066243","DOI":"10.1136\/bmjopen-2022-066243","article-title":"Association between serum uric acid\/HDL-cholesterol ratio and chronic kidney disease: a cross-sectional study based on a health check-up population","volume":"12","author":"Cheng","year":"2022","journal-title":"BMJ Open."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1269580","DOI":"10.3389\/fendo.2023.1269580","article-title":"Association between cumulative uric acid to high-density lipoprotein cholesterol ratio and the incidence and progression of chronic kidney disease","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"24353","DOI":"10.1038\/s41598-025-09999-5","article-title":"Association between uric acid to high-density lipoprotein cholesterol ratio and diabetic kidney disease in US adults","volume":"15","author":"Qin","year":"2025","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.3390\/ijms23105719","article-title":"La Manna G, et al. Precision nephrology in patients with diabetes and chronic kidney disease","volume":"23","author":"Provenzano","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1660820","DOI":"10.3389\/fnut.2025.1660820","article-title":"Glycemic control modifies LDL-C-DKD risk: a U-shaped association in well-controlled type 2 diabetes","volume":"12","author":"Zheng","year":"2025","journal-title":"Front Nutr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12944-025-02632-4","article-title":"Sex-specific and metabolic subgroup heterogeneity in high-density lipoprotein cholesterol associations with diabetic kidney disease risk: a retrospective cohort study","volume":"24","author":"Wang","year":"2025","journal-title":"Lipids Health Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e005581","DOI":"10.1136\/bmjdrc-2025-005581","article-title":"High-density lipoprotein cholesterol and kidney disease progression in patients with type 2 diabetes mellitus: the Fukushima Cohort Study","volume":"13","author":"Nakada","year":"2025","journal-title":"BMJ Open Diab Res Care."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/0118715303369433250914053054.","article-title":"Nonlinear association between uric acid to high-density lipoprotein cholesterol ratio and diabetic kidney disease: evidence from NHANES 2007-2018","author":"Wei","year":"2025","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/jdi.70107","article-title":"Uric acid to high-density lipoprotein cholesterol ratio is associated with the prevalence of diabetic kidney disease in euthyroid patients with type 1 diabetes mellitus in China: a multicenter cross-sectional study","volume":"16","author":"Zhao","year":"2025","journal-title":"J Diab Investig."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737159.2026.2663523","article-title":"Association between the uric acid-to-HDL-cholesterol ratio and diabetic kidney disease in individuals with type 2 diabetes and NAFLD: evidence from NHANES and an external hospital cohort","volume":"23","author":"Gong","year":"2026","journal-title":"Expert Rev Mol Diagn."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1497449","DOI":"10.1155\/2021\/1497449","article-title":"Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment","volume":"2021","author":"Samsu","year":"2021","journal-title":"Biomed Res Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/antiox10071143","article-title":"Metabolic changes and oxidative stress in diabetic kidney disease","volume":"10","author":"Sakashita","year":"2021","journal-title":"Antioxidants."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jdi.14086","article-title":"Association between serum uric acid-to-high-density lipoprotein cholesterol ratio and insulin resistance in patients with type 2 diabetes mellitus","volume":"15","author":"Zhou","year":"2024","journal-title":"J Diabetes Investig."},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1806-9282.65.1.9","article-title":"Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus","volume":"65","author":"Kocak","year":"2019","journal-title":"Rev Assoc Med Bras."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/jcm15062160","article-title":"Baseline uric acid-to-HDL cholesterol ratio predicts peritoneal membrane failure in peritoneal dialysis patients","volume":"15","author":"Tomar","year":"2026","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","article-title":"Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)","volume":"22","author":"Wada","year":"2018","journal-title":"Clin Exp Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1053\/j.ajkd.2018.07.022","article-title":"Urate-lowering therapy for preventing kidney disease progression: are we there yet?","volume":"72","author":"Tiku","year":"2018","journal-title":"Am J Kidney Dis."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1887095\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:56Z","timestamp":1785130856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1887095\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":31,"alternative-id":["10.3389\/fnut.2026.1887095"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1887095","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1887095"}}